Seaport Therapeutics
@seaporttx.bsky.social
29 followers 6 following 41 posts
We're a clinical-stage biopharmaceutical company advancing the development of neuropsychiatric medicines in areas of high unmet patient needs.
Posts Media Videos Starter Packs
seaporttx.bsky.social
We convened top neuropsych experts, sell-side analysts, investors, & biopharma leaders for a unique roundtable discussion on the opportunities & excitement in #neuropsychiatry & what’s next as #MentalHealth conditions continue to impact millions globally. See below for some takeaways
seaporttx.bsky.social
Tune in today at 11:45 AM ET to hear our CFO Lauren White & COO Eric Green present at the Oppenheimer Private Life Sciences Company Showcase. Live webcast: bit.ly/4nllNke & replay available on our website: seaporttx.com/news-papers/
seaporttx.bsky.social
We’re a Fierce Biotech Fierce 15 winner! Our Glyph platform, proven team, & focus on validated mechanisms put us among the most “innovative & visionary” companies as we advance clinical programs aiming to deliver new medicines for #depression & #anxiety. bit.ly/4msojnm
seaporttx.bsky.social
Looking forward to two upcoming investor conferences: 1x1s & company presentation at Oppenheimer's Private Life Sciences Company Showcase on 9/25 at 11:45am ET & 1x1s at the 5th Annual Needham Private Biotech & MedTech Company Forum, held 10/14-10/15. bit.ly/42z6Fr1
seaporttx.bsky.social
Pleased to share the first participant has been dosed in our Ph1 study of GlyphAgo™ (SPT-320). This is our 2nd therapeutic candidate in clinical development & represents an important clinical advancement for patients w/GAD. bit.ly/4meQFl0
seaporttx.bsky.social
Dan Bonner, Co-Founder & SVP, Platform at Seaport will present at the Neuropsychiatric Drug Development Summit in Boston on 9/11 at 1:30pm to share insights on the discovery & selection of novel lymphatic-targeted prodrug candidates using clinical evidence ter.li/42ap36
seaporttx.bsky.social
Congrats to COBENFY & ZURZUVAE teams for 2025 #PrixGalien Best Pharmaceutical Product noms! Kudos to all involved (@PureTechh, Karuna for COBENFY) in the successful journeys, notably Seaport's Dr. Steve Paul for his role in advancing both nominated drugs bit.ly/3V6cx72
seaporttx.bsky.social
This summer, the team had a blast together building meaningful connections. From everyday moments to unique outings, these experiences reinforce our bonds & remind us of our shared mission to serve those with #MentalHealth conditions like #depression & #anxiety. Excited for more!
seaporttx.bsky.social
We're featured in @natbiotech.nature.com's “Editor’s Pick” for our work developing #neuropsychiatric medicines using our proprietary Glyph platform. Read about how we're advancing novel therapies with clinically validated mechanisms for depression & anxiety bit.ly/47f4jke
seaporttx.bsky.social
Our CFO, Lauren White, joins Boston Business Journal's “Biotech’s Future – Innovation, AI and our Competitive Edge” panel this Thursday with other industry leaders to discuss the future of biotech & life sciences in MA. Don’t miss this dynamic discussion! bit.ly/44VDFLK
seaporttx.bsky.social
CEO @daphnezohar.bsky.social took Brad Loncar @biotechtv.bsky.social on a tour of our office located in heart of Boston’s Seaport District, which is uniquely designed to foster collaboration, happiness & teamwork as we work together to develop new medicines for #depression & #anxiety. Check it out!
biotechtv.bsky.social
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐓𝐨𝐮𝐫: BiotechTV visited the new offices of @seaporttx.bsky.social today and was given a tour by Founder & CEO @daphnezohar.bsky.social
seaporttx.bsky.social
Pleased to announce the first patient has been dosed in our Ph2b BUOY-1 study of GlyphAllo™ (SPT-300) in #MDD w/ or w/o anxious distress, an important milestone for Seaport’s pipeline that brings us closer to a potential new treatment for patients w/ MDD: bit.ly/3Uhn3YB
seaporttx.bsky.social
The Seaport crew kicked off summer with a fun gathering! Great opportunity to connect out of the office, strengthening our mission to develop life-changing medicines for #neuropsychiatric disorders. Looking forward to more moments together and progress towards transforming lives!
seaporttx.bsky.social
Our Co-founder & Board Chair Dr. Steve Paul was at Royalty Pharma’s #ABI25 for a fireside chat on the neuropsych renaissance. A pioneer in neuropsychiatric drug development, he shared insights into this new era of CNS medicines, including Seaport’s work in #depression & #anxiety
seaporttx.bsky.social
As #MentalHealthMonth closes, we welcomed a @namicommunicate.bsky.social patient representative to share his journey w/ mental health conditions. His story inspires our work at Seaport to help those struggling & develop new medicines for #depression & #anxiety. More: www.nami.org
seaporttx.bsky.social
This #MentalHealthMonth, we joined @namicommunicate.bsky.social's annual #NAMIWalks to combat stigma & promote mental health awareness. We stand with those affected by mental illness & are dedicated to developing new medicines for #depression & #anxiety. More about NAMI www.nami.org
seaporttx.bsky.social
Our CMO Tony Loebel & @afspnational.bsky.social board member attended the 2025 Lifesavers Gala to honor progress in the fight against suicide. In recognition of #MentalHealthAwarenessMonth, we're proud Tony represented Seaport to help save lives & bring hope to those affected by suicide.
seaporttx.bsky.social
#Depression & #anxiety are among the most common & disabling #mentalhealth conditions. This #MentalHealthAwarenessMonth we're spotlighting our commitment to developing better medicines & reducing the stigma for those dealing w/these conditions. Learn more: www.seaporttx.com
seaporttx.bsky.social
"Neurology is back” as detailed in Nature Biotech spotlighting "Seaport’s approach, like that of Karuna, is to resurrect drugs that showed clinical efficacy, but which had other issues that limited their impact on patients." Also mentioned $JNJ, $RAPP, $BHVN & others: doi.org/10.1038/s415...
seaporttx.bsky.social
We're at #SOBP2025 to present new preclinical data on SPT-320, a novel oral prodrug of agomelatine. SPT-320 increased lymphatic transport >50% compared to <1% agomelatine alone & increased plasma exposure >10-fold. SPT-320 progressing into clinic for #GAD. bit.ly/4ixtOzs
seaporttx.bsky.social
Congrats @daphnezohar.bsky.social, named to @statnews.com #STATUSList, "the ultimate list of leaders in health, medicine, & science," for founding Seaport & raising $325M. “That’s big & her influence on the biotech field extends beyond that” & cofounding Karuna & PureTech bit.ly/4coOF6B
seaporttx.bsky.social
Seaport aims to develop better treatments for depression & anxiety. This commitment comes from our exceptional team, all rowing in the same direction to deliver new drugs to make the lives of patients better. What inspires us daily? Hear from our team!
seaporttx.bsky.social
1 year ago, we launched w/ a mission to deliver new medicines to those suffering from depression & anxiety. What a year! We raised $325M, built a stellar team, shared important scientific & clinical work, & advanced our clinical-stage pipeline & Glyph platform: seaporttx.com
seaporttx.bsky.social
Listen in today at 3:45pm EDT as Michael Chen, our Co-Founder and CSO and Lauren White our CFO present at the 24th Annual Needham Healthcare Conference. 

Tune in here: bit.ly/4hWh4lq

In case you missed it: seaporttx.com/news-papers/